The CEO of Cytovia Therapeutics Dr. Daniel Teper joins The Watchlist to discuss the company's focus on building a next-generation immuno-oncology therapeutics platform. The company was founded in 2019, and develops NK-cell and NK-engager antibody platforms to improve tumor-specific targeting in oncology patients. Dr. Teper also highlights the company's SPAC merger with Isleworth Healthcare.
The Watch List
28 Apr 2022
SHARE
The Watch List
17 Feb 2023
The Watch List
31 Jan 2023
Next Gen Investing
18 Apr 2023
The Watch List
27 Feb 2023
Market On Close
24 Feb 2023